# ACT-293987 in Pulmonary Arterial Hypertension

Study · id `cardio:ct-nct01112306` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01112306](<https://clinicaltrials.gov/study/NCT01112306>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01112306

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 709 participants.

## Technical summary

Registry record NCT01112306. Allocation not applicable; no masking; primary purpose treatment. Start 2010-07-07 (actual); primary completion 2021-08-26 (actual). Results posted on 2022-09-19.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 709 participants (enrolled count; ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Started: 2010-07-07 (actual) (ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Primary completion: 2021-08-26 (actual) (ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Completion: 2021-08-26 (actual) (ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Results first posted: 2022-09-19 (ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belarus; Belgium; Canada; Chile; China; Colombia; Czechia; Denmark; France; Germany; Greece; Hungary; India; Ireland; Israel; Malaysia; Mexico; Netherlands; Peru; Poland; Romania; Russia; Serbia; Singapore; Slovakia; South Korea; Spain; Sweden; Switzerland; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01112306, source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01112306-2025-03-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: ACT-293987 in Pulmonary Arterial Hypertension
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): ACT-293987
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: fd49496460f78231fadee783aeb83f28867b06f7205b70632f9173ba3c64a836
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
